New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition
Artelo Biosciences announced the publication of a review article in the British Journal of Clinical Pharmacology analyzing over 50 studies on low-dose CBD products. The review concluded that non-prescription CBD doses typically found in retail products (≤2.5 mg/kg) provide insufficient exposure for therapeutic benefit, highlighting a need for optimized formulations. The company stated that its proprietary ART12.11 cocrystal composition is designed to address these bioavailability challenges, with patent protection secured in the U.S.
Key figures
- Patent expiry
- December 10, 2038
- Low dose limit
- ≤2.5 mg/kg or ≤175 mg/day
- Studies analyzed
- 50+
- Patent territories
- 20+ additional countries
- Exposure gap vs therapeutic dose
- 5–100 times lower
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.